Multiple-Session Subthreshold Micropulse Laser Therapy for Exudative Perifoveal Vascular Anomalous Complex: A Case Report

Perifoveal anomalous exudative vascular complex (PEVAC) was first described in 2011. Since then, individual clinical cases and a couple of case series have been published, and their characteristics have been studied in multi-modal images. To date, there is no consensus on its treatment. Initially, it was thought that PEVACs could be left to spontaneous evolution because they presented a slow progression. But it has been shown that the growth of the lesion covers a spectrum from non-exudative lesions to PEVAC with vision impairment over time. We present an updated bibliographic review of this pathology. We explain the changes in the diagnostic criteria that have been undergone. And we focus the discussion on selective treatment with focal laser, which has shown an excellent anatomical response and visual improvement or stabilization in the cases described and in our series of three patients systematically treated with focal laser. [ Ophthalmic Surg Lasers Imaging Retina 2023;54:43–49.]

show abstract

Multiple-Session Subthreshold Micropulse Laser Therapy for Exudative Perifoveal Vascular Anomalous Complex: A Case Report

Abstract: The authors present a follow-up of exudative, perifoveal, vascular anomalous complex in a 65-year-old woman treated with 532-nm subthreshold micropulse laser that was unresponsive to intravitreal injection treatment.

Cited by 3 publications

References 9 publications

Aflibercept/bevacizumab

Aflibercept/bevacizumab

Retinal artery aneurysmal abnormalities

Selective Focal Laser Therapy as the Primary Treatment for Exudative Perifoveal Vascular Anomalous Complex (ePVAC): Case Series and Literature Review

Contact Info

Product

Resources

About